altoneuroscience.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $253.17MM
Alto Neurosciences is a biopharma company that uses biomarkers of the brain to understand prospective drug therapies for psychiatric care of patients. Alto Neurosciences specializes in precision medicine, and has established a pipeline of treatments for various mental health conditions such as post-traumatic stress disorders (PTSD) and depression.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
11/21/2023 | Series C | $50.31MM | $xx.xx | $235.65MM | Alexandria Venture Investments, Alkeon Capital, Alpha Wave Ventures, Eli Lilly & Company, Franklin Templeton, Invivium Capital, Lightswitch Capital, Point72, Whatif Ventures, Windham Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
10,674,967
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Alkeon Capital, Alpha Wave Ventures, Eli Lilly & Company, Franklin Templeton, Invivium Capital, Lightswitch Capital, Point72, Whatif Ventures, Windham Venture Partners
|
||||||
01/30/2023 | Series B | $59.26MM | $xx.xx | $218.32MM | Alkeon Capital, Alpha Wave Ventures, Aperion Group, Gaingels, Korify Capital, Lightswitch Capital, Novartis Pharma Ag, Sobrato Capital, Valor Equity Partners, Vine Ventures, What If Ventures, Windham Venture Partners | |
Price per Share
$xx.xx
Shares Outstanding
9,876,955
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alkeon Capital, Alpha Wave Ventures, Aperion Group, Gaingels, Korify Capital, Lightswitch Capital, Novartis Pharma Ag, Sobrato Capital, Valor Equity Partners, Vine Ventures, What If Ventures, Windham Venture Partners
|
||||||
10/14/2021 | Series A | $34.08MM | $xx.xx | $128.77MM | Able Partners, Aperion Investment Group, Tim Kendall, What If Ventures, Windham Partners | |
Price per Share
$xx.xx
Shares Outstanding
7,250,992
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Able Partners, Aperion Investment Group, Tim Kendall, What If Ventures, Windham Partners
|
||||||
09/30/2019 | Series Seed | $7.72MM | $xx.xx | $30.89MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
3,708,682
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|